Switch to:
Also traded in: Denmark, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 28.98
OTCPK:NONOF's Cash-to-Debt is ranked lower than
51% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. OTCPK:NONOF: 28.98 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:NONOF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 21.94 Max: N/A
Current: 28.98
Equity-to-Asset 0.43
OTCPK:NONOF's Equity-to-Asset is ranked lower than
76% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OTCPK:NONOF: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:NONOF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.62 Max: 0.73
Current: 0.43
0.42
0.73
Interest Coverage 109.28
OTCPK:NONOF's Interest Coverage is ranked lower than
74% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCPK:NONOF: 109.28 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:NONOF' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 279.29 Max: 884.41
Current: 109.28
9.18
884.41
Piotroski F-Score: 7
Altman Z-Score: 11.96
Beneish M-Score: -3.27
WACC vs ROIC
9.25%
151.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 43.90
OTCPK:NONOF's Operating Margin % is ranked higher than
96% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. OTCPK:NONOF: 43.90 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:NONOF' s Operating Margin % Range Over the Past 10 Years
Min: 21.38  Med: 35.7 Max: 45.81
Current: 43.9
21.38
45.81
Net Margin % 34.18
OTCPK:NONOF's Net Margin % is ranked higher than
94% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. OTCPK:NONOF: 34.18 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:NONOF' s Net Margin % Range Over the Past 10 Years
Min: 20.38  Med: 26.62 Max: 34.18
Current: 34.18
20.38
34.18
ROE % 93.41
OTCPK:NONOF's ROE % is ranked higher than
99% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. OTCPK:NONOF: 93.41 )
Ranked among companies with meaningful ROE % only.
OTCPK:NONOF' s ROE % Range Over the Past 10 Years
Min: 27.38  Med: 50.43 Max: 93.41
Current: 93.41
27.38
93.41
ROA % 42.94
OTCPK:NONOF's ROA % is ranked higher than
98% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. OTCPK:NONOF: 42.94 )
Ranked among companies with meaningful ROA % only.
OTCPK:NONOF' s ROA % Range Over the Past 10 Years
Min: 18.46  Med: 30 Max: 42.94
Current: 42.94
18.46
42.94
ROC (Joel Greenblatt) % 173.01
OTCPK:NONOF's ROC (Joel Greenblatt) % is ranked higher than
96% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. OTCPK:NONOF: 173.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:NONOF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43  Med: 107.33 Max: 178.92
Current: 173.01
43
178.92
3-Year Revenue Growth Rate 12.40
OTCPK:NONOF's 3-Year Revenue Growth Rate is ranked higher than
64% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OTCPK:NONOF: 12.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:NONOF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.3  Med: 12.4 Max: 127.9
Current: 12.4
-46.3
127.9
3-Year EBITDA Growth Rate 15.30
OTCPK:NONOF's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. OTCPK:NONOF: 15.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:NONOF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: 14.7 Max: 130.3
Current: 15.3
-44.4
130.3
3-Year EPS without NRI Growth Rate 17.00
OTCPK:NONOF's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OTCPK:NONOF: 17.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:NONOF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 16.7 Max: 36.9
Current: 17
1.3
36.9
GuruFocus has detected 1 Warning Sign with Novo Nordisk A/S $OTCPK:NONOF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:NONOF's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:CELG, NAS:AMGN, NAS:GILD, NAS:BIIB, NAS:REGN, OTCPK:SHPGF, OTCPK:CSLLY, NAS:VRTX, OTCPK:ALIOY, NAS:ALXN, NAS:INCY, OTCPK:GIKLY, NAS:BMRN, OTCPK:GMXAY, OTCPK:UCBJY, OTCPK:NVZMY, NAS:JAZZ, NAS:ALKS, NAS:SGEN, NAS:TSRO » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NVON.Mexico, NOVOB.Switzerland, 0QIU.UK, NVO.USA,
Headquarter Location:Denmark
Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals.

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Top Ranked Articles about Novo Nordisk A/S

FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia
Novo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United States
Novo Nordisk Invites the Community to Unmask Everyday Heroes in Recognition of World Hemophilia Day
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – NVO

NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired American Depositary Receipts of Novo Nordisk A/S (:NVO) between February 5, 2015 and October 27, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to: http://www.zlk.com/pslra/novo-nordisk-as or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that during the Class Period, Novo Nordisk issued materially false and misleading earnings and forecasts; said reports were inflated by collusive price fixing concerning the Company’s insulin drugs. The complaint further alleges that the Company misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers. If you suffered a loss in Novo Nordisk you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
NVO Lead Plaintiff Deadline Reminder: Hagens Berman Reminds Novo Nordisk Investors of March 13, 2017 Lead Plaintiff Deadline

SAN FRANCISCO, March 06, 2017 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Novo Nordisk A/S (:NVO) of the March 13, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of NVO between February 5, 2015 and October 27, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit: https://www.hbsslaw.com/cases/NVO or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected]. On October 28, 2016, after repeatedly assuring investors of sales and profit growth, NVO announced its second consecutive quarter of disappointing earnings and slashed long-term profit-growth forecasts by 50%.  The Company also revealed it was under investigation by the U.S. Attorney’s Office for potentially improper arrangements with pharmacy benefits managers who purchase NVO’s insulin products.  This news drove the price of the Company’s ADRs down approximately 13%. “We’re focused on NVO’s insulin- and other- pricing matters and Defendants’ growth-related statements,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding NVO should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email [email protected]. About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000

Read more...
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Novo Nordisk A/S (NVO) To Contact The Firm
STEVENSON, Md., March 05, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Novo Nordisk A/S (:NVO) (“Novo Nordisk” or the “Company”) American Depositary Receipts (“ADRs”) expanding the class period to February 5, 2015 and October 27, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Novo Nordisk ADRs during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Company’s reported earnings and forecasts were inflated through the collusive price fixing of the Company’s insulin drugs.According to the complaint, following an August 5, 2016 announcement of disappointing earnings for the second quarter of 2016, an August 9, 2016 analyst report that disclosed that major net pricing upgrades in the U.S. will be the exceptions as opposed to the norm, and there will be no quick rebound from the Company’s stagnated growth, and an October 28, 2016 announcement that the Company was cutting its long-term profit growth by 50% and that it received a Civil Investigative Demand from the U.S. Attorney’s Office for the Southern District of New York seeking information relating to contracts and business relationships concerning its insulin products, the value of Novo Nordisk American Depositary shares declined significantly.If you have suffered a loss in excess of $100,000 from investment in Novo Nordisk ADRs purchased on or after February 5, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
NOVO NORDISK SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novo Nordisk A/S – (NVO)

NEW ORLEANS, March 03, 2017 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Novo Nordisk A/S (:NVO), if they purchased the Company’s American Depository Receipts (“ADRs”) between the expanded period of February 5, 2015 and October 27, 2016, inclusive (the “Class Period”).  The action is pending in the United States District Court for the District of New Jersey. 
What You May Do If you purchased ADRs of Novo Nordisk and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 13, 2017. About the Lawsuit Novo Nordisk and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  On August 5, 2016, the Company announced disappointing earnings for the 2016 second quarter.  Then, on October 28, 2016, the Company disclosed that it was cutting its long-term profit growth by 50% and that it had received a Civil Investigative Demand from the U.S. Attorney’s Office for the Southern District of New York seeking information relating to contracts and business relationships concerning its insulin products. On this news, the price of Novo Nordisk’s ADRs plummeted.  About Kahn Swick & Foti, LLC KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447

Read more...
New Features: Individual Portfolio Tracker and Value Screens Tracker A detailed discussion of 2 features on GuruFocus’ new home page
As discussed in a previous article, GuruFocus launched a new, user-friendly home page in February. The page contains two useful features: “Individual Portfolio Tracker” and the “Value Screens Tracker.” The former allows you to view snapshots of each of your portfolios and view alerts. If you scroll down to the “Value Screens” section, you will notice green and red icons on each of the tabs. These numbers track changes in the value screener record. Read more...
NVO DEADLINE NOTICE: Rosen Law Firm Reminds Novo Nordisk A/S Investors of Important March 13 Deadline in Class Action – NVO

NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Novo Nordisk A/S securities (: NVO) from April 30, 2015 through October 27, 2016, inclusive (the “Class Period”) of the important March 13, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Novo Nordisk investors under the federal securities laws. To join the Novo Nordisk class action, go to http://rosenlegal.com/cases-1029.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period Novo Nordisk reported materially false and misleading earnings and forecasts in that they were inflated through the collusive price fixing of Novo Nordisk’s insulin drugs. The lawsuit also alleges that Novo Nordisk misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.  When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1029.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Contact Information:
      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Kevin Chan, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

Read more...
NVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017

NEW YORK, Feb. 08, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Novo Nordisk A/S (NYSE:NYSE:NVO) securities between April 30, 2015 and October 27, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/novo-nordisk-as. There is no cost or obligation to you. According to the complaint, during the Class Period, Novo Nordisk issued materially false and misleading earnings and forecasts; said reports were inflated by collusive price fixing concerning the Company’s insulin drugs. The complaint further alleges that the Company misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers. If you suffered a loss in Novo Nordisk you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/novo-nordisk-as. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 18.84
NONOF's PE Ratio is ranked higher than
70% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.55 vs. NONOF: 18.84 )
Ranked among companies with meaningful PE Ratio only.
NONOF' s PE Ratio Range Over the Past 10 Years
Min: 12.13  Med: 23.56 Max: 34.41
Current: 18.84
12.13
34.41
Forward PE Ratio 18.62
NONOF's Forward PE Ratio is ranked higher than
60% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 22.68 vs. NONOF: 18.62 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.84
NONOF's PE Ratio without NRI is ranked higher than
72% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.76 vs. NONOF: 18.84 )
Ranked among companies with meaningful PE Ratio without NRI only.
NONOF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.13  Med: 23.53 Max: 34.41
Current: 18.84
12.13
34.41
Price-to-Owner-Earnings 19.45
NONOF's Price-to-Owner-Earnings is ranked higher than
68% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.51 vs. NONOF: 19.45 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NONOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.81  Med: 27.1 Max: 60.24
Current: 19.45
13.81
60.24
PB Ratio 17.90
NONOF's PB Ratio is ranked lower than
92% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NONOF: 17.90 )
Ranked among companies with meaningful PB Ratio only.
NONOF' s PB Ratio Range Over the Past 10 Years
Min: 3.68  Med: 9.41 Max: 31.9
Current: 17.9
3.68
31.9
PS Ratio 6.43
NONOF's PS Ratio is ranked higher than
64% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. NONOF: 6.43 )
Ranked among companies with meaningful PS Ratio only.
NONOF' s PS Ratio Range Over the Past 10 Years
Min: 2.81  Med: 5.87 Max: 10.99
Current: 6.43
2.81
10.99
Price-to-Free-Cash-Flow 16.51
NONOF's Price-to-Free-Cash-Flow is ranked higher than
68% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 28.96 vs. NONOF: 16.51 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NONOF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.07  Med: 24.32 Max: 46.97
Current: 16.51
12.07
46.97
Price-to-Operating-Cash-Flow 13.75
NONOF's Price-to-Operating-Cash-Flow is ranked higher than
73% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 25.50 vs. NONOF: 13.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NONOF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.91  Med: 19.83 Max: 32.48
Current: 13.75
9.91
32.48
EV-to-EBIT 14.56
NONOF's EV-to-EBIT is ranked higher than
64% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. NONOF: 14.56 )
Ranked among companies with meaningful EV-to-EBIT only.
NONOF' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.7 Max: 25.7
Current: 14.56
9.2
25.7
EV-to-EBITDA 13.65
NONOF's EV-to-EBITDA is ranked higher than
61% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. NONOF: 13.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
NONOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16 Max: 23.6
Current: 13.65
8.2
23.6
PEG Ratio 1.11
NONOF's PEG Ratio is ranked higher than
66% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 2.15 vs. NONOF: 1.11 )
Ranked among companies with meaningful PEG Ratio only.
NONOF' s PEG Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.16 Max: 5.14
Current: 1.11
0.7
5.14
Shiller PE Ratio 33.98
NONOF's Shiller PE Ratio is ranked higher than
67% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.27 vs. NONOF: 33.98 )
Ranked among companies with meaningful Shiller PE Ratio only.
NONOF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.12  Med: 42.63 Max: 67.93
Current: 33.98
23.12
67.93
Current Ratio 1.14
NONOF's Current Ratio is ranked lower than
86% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NONOF: 1.14 )
Ranked among companies with meaningful Current Ratio only.
NONOF' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.97 Max: 3.09
Current: 1.14
1.04
3.09
Quick Ratio 0.83
NONOF's Quick Ratio is ranked lower than
87% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NONOF: 0.83 )
Ranked among companies with meaningful Quick Ratio only.
NONOF' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.33 Max: 2.6
Current: 0.83
0.74
2.6
Days Inventory 298.23
NONOF's Days Inventory is ranked lower than
85% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. NONOF: 298.23 )
Ranked among companies with meaningful Days Inventory only.
NONOF' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 282.52 Max: 343.56
Current: 298.23
246.45
343.56
Days Sales Outstanding 54.94
NONOF's Days Sales Outstanding is ranked higher than
58% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NONOF: 54.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
NONOF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.9 Max: 66.07
Current: 54.94
45.09
66.07
Days Payable 80.26
NONOF's Days Payable is ranked higher than
64% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. NONOF: 80.26 )
Ranked among companies with meaningful Days Payable only.
NONOF' s Days Payable Range Over the Past 10 Years
Min: 72.54  Med: 100.02 Max: 127.69
Current: 80.26
72.54
127.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.57
NONOF's Dividend Yield % is ranked higher than
81% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. NONOF: 2.57 )
Ranked among companies with meaningful Dividend Yield % only.
NONOF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.93  Med: 1.57 Max: 4.17
Current: 2.57
0.93
4.17
Dividend Payout Ratio 0.50
NONOF's Dividend Payout Ratio is ranked lower than
71% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. NONOF: 0.50 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NONOF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.63
Current: 0.5
0.26
0.63
3-Year Dividend Growth Rate 37.70
NONOF's 3-Year Dividend Growth Rate is ranked higher than
86% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. NONOF: 37.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NONOF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.6 Max: 37.7
Current: 37.7
0
37.7
Forward Dividend Yield % 2.57
NONOF's Forward Dividend Yield % is ranked higher than
88% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NONOF: 2.57 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 10.26
NONOF's 5-Year Yield-on-Cost % is ranked higher than
98% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.57 vs. NONOF: 10.26 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NONOF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.71  Med: 6.27 Max: 16.65
Current: 10.26
3.71
16.65
3-Year Average Share Buyback Ratio 1.80
NONOF's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NONOF: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NONOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: 0.7 Max: 8
Current: 1.8
-13.6
8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 436.50
NONOF's Price-to-Net-Current-Asset-Value is ranked lower than
100% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NONOF: 436.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NONOF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.79  Med: 24.94 Max: 696.47
Current: 436.5
11.79
696.47
Price-to-Tangible-Book 19.23
NONOF's Price-to-Tangible-Book is ranked lower than
89% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. NONOF: 19.23 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NONOF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 7.38 Max: 31.52
Current: 19.23
3.14
31.52
Price-to-Intrinsic-Value-Projected-FCF 1.64
NONOF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
77% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 3.46 vs. NONOF: 1.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NONOF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.36  Med: 2.32 Max: 7.38
Current: 1.64
1.36
7.38
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.66
NONOF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
85% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. NONOF: 0.66 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.10
NONOF's Price-to-Median-PS-Value is ranked lower than
61% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NONOF: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NONOF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.83 Max: 1.77
Current: 1.1
0.13
1.77
Price-to-Peter-Lynch-Fair-Value 0.99
NONOF's Price-to-Peter-Lynch-Fair-Value is ranked higher than
79% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. NONOF: 0.99 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NONOF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.02 Max: 3.78
Current: 0.99
0.19
3.78
Price-to-Graham-Number 4.01
NONOF's Price-to-Graham-Number is ranked lower than
69% of the 190 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. NONOF: 4.01 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NONOF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.58  Med: 2.79 Max: 6.75
Current: 4.01
1.58
6.75
Earnings Yield (Greenblatt) % 6.87
NONOF's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NONOF: 6.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NONOF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.9  Med: 6 Max: 10.8
Current: 6.87
3.9
10.8
Forward Rate of Return (Yacktman) % 22.70
NONOF's Forward Rate of Return (Yacktman) % is ranked higher than
63% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. NONOF: 22.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NONOF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.5  Med: 22.9 Max: 33.5
Current: 22.7
7.5
33.5

More Statistics

Revenue (TTM) (Mil) $16,578.90
EPS (TTM) $ 2.25
Beta0.72
Short Percentage of Float0.00%
52-Week Range $31.07 - 58.05
Shares Outstanding (Mil)2,550.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 17,475 18,461 19,543
EPS ($) 2.32 2.54 2.66
EPS without NRI ($) 2.32 2.54 2.66
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.70%
Dividends per Share ($) 1.37 1.46 1.77
» More Articles for NONOF

Headlines

Articles On GuruFocus.com
STORE Capital: Thank You, Warren Buffett Jun 28 2017 
Test2 Jun 28 2017 
US Market Indexes Higher on Wednesday Jun 28 2017 
Test Jun 28 2017 
British Pound Moving Higher Against US Dollar Jun 28 2017 
Bain Capital's Offer to Buy German Stada Falls Through Jun 28 2017 
Test Jun 28 2017 
Growing Competition Will Continue to Hurt Fitbit Jun 28 2017 
Rich Cigars Debuts in the OTC Pink Sheets Market Jun 28 2017 
Some More Timeless Advice From the Intelligent Investor Jun 28 2017 

More From Other Websites
The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk Jun 26 2017
3 Best Healthcare Dividend Stocks of the 21st Century (So Far) Jun 24 2017
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod Jun 23 2017
Why You Should Add Novo Nordisk Stock to Your Portfolio Jun 22 2017
Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion Jun 21 2017
[$$] Global pharma sales forecasts cut amid pricing pressures Jun 20 2017
Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug Jun 14 2017
Why Novo Nordisk A/S (ADR) Jumped 10.6% In May Jun 10 2017
Novo Nordisk looks to shore up European market share Jun 02 2017
Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B Jun 01 2017
Big Pharma Diabetes Drugs Not So Sweet. What's in Store? May 31 2017
Novo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial May 23 2017
The 3 Best Obesity-Drug Stocks to Buy in 2017 May 19 2017
Novelion CEO quits Novo Nordisk board due to NASH conflict May 16 2017
The prices for life-saving diabetes medications have increased again May 15 2017
Novo Nordisk Sees More Competition in U.S. Drug Prices May 10 2017
Novo Nordisk CEO: Most growth coming from organic pipelin... May 10 2017
Novo Nordisk A/S :NONOF-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017 May 08 2017
Novo Nordisk A/S Jumps Over Its Lowered Bar May 04 2017
Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y May 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}